Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Laser showdown: which light best zaps spider veins?

NCT ID NCT07678697

Symptom relief Sponsor: Ain Shams University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study compares two laser treatments—Nd:YAG versus diode—both combined with injection sclerotherapy, for removing reticular veins and spider veins (telangiectasias) using the CLaCS technique. About 80 adults aged 18 to 60 with these veins will receive one of the two laser types. Researchers will measure how well each clears the veins, pain levels, and patient satisfaction.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Nd:YAG laser or diode laser combined with injection sclerotherapy
What this could lead to
If one laser works better, it could become the preferred option for clearing spider veins with less pain and higher satisfaction.
What could go wrong
This is a small, early-stage comparison study. Results may not apply to all skin types or vein severities, and both treatments carry risks like bruising or incomplete clearance.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18-60 years. * Both sexes. * Presence of reticular veins and/or telangiectasias (CEAP classification C1). * Fitzpatrick skin types II-V. * Patients seeking cosmetic treatment. Exclusion Criteria: * Pregnancy or lactation. * History of deep vein thrombosis. * Coagulation disorders. * Allergy to sclerosant agents. * Active skin infection at treatment site. * Previous treatment of target veins within 6 months. * Great saphenous vein or short saphenous vein incompetence. * Deep venous insufficiency or thrombosis. * Abnormal venous duplex findings.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Clacs technique are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

livedo reticularis telangiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Clacs technique Diode laser ND:yag laser Reticular veins Sclerotherapy Telangiectasias

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ain Shams University

    RECRUITING

    Cairo, 11591, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.